Itgo 100 Capsule contains Itraconazole 100 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itgo 100 Capsule is primarily prescribed for infections caused by dermatophytes, yeasts, and molds, including but not limited to onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The drug demonstrates broad-spectrum antifungal activity and is effective in both immunocompetent and immunocompromised patients. It is administered orally, with absorption enhanced when taken with food. Dosage and duration depend on the type and severity of infection, and treatment should be guided by clinical response and mycological assessments. Caution is advised in patients with hepatic impairment, and monitoring of liver function tests is recommended during prolonged therapy. Potential drug interactions exist due to itraconazole's inhibition of cytochrome P450 enzymes, necessitating careful review of concomitant medications. Itgo 100 Capsule should be used under medical supervision to ensure safety and efficacy.